

Dipti Talaulikar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/845435/publications.pdf>

Version: 2024-02-01

58
papers

1,210
citations

430874

18
h-index

395702

33
g-index

59
all docs

59
docs citations

59
times ranked

1990
citing authors

#	ARTICLE	IF	CITATIONS
1	Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL. <i>Blood</i> , 2018, 131, 1809-1819.	1.4	231
2	Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. <i>Lancet Haematology</i> , 2020, 7, e827-e837.	4.6	96
3	Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study. <i>Lancet Haematology</i> , 2015, 2, e445-e455.	4.6	74
4	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. <i>Blood</i> , 2019, 133, 299-305.	1.4	69
5	LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2020, 4, 1367-1377.	5.2	66
6	The T-cell Receptor Repertoire Influences the Tumor Microenvironment and Is Associated with Survival in Aggressive B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 1820-1828.	7.0	65
7	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , 2020, 4, 6009-6018.	5.2	57
8	The tumour microenvironment is immunotolerogenic and a principal determinant of patient outcome in EBV-positive diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2019, 103, 200-207.	2.2	42
9	The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma. <i>Clinical Cancer Research</i> , 2021, 27, 6323-6332.	7.0	42
10	Lymphocytopenia as a prognostic marker for diffuse large B cell lymphomas. <i>Leukemia and Lymphoma</i> , 2008, 49, 959-964.	1.3	39
11	Health-related quality of life in chronic coagulation disorders. <i>Haemophilia</i> , 2006, 12, 633-642.	2.1	30
12	A comparative study of the quality of DNA obtained from fresh frozen and formalin-fixed decalcified paraffin-embedded bone marrow trephine biopsy specimens using two different methods. <i>Journal of Clinical Pathology</i> , 2007, 61, 119-123.	2.0	27
13	Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. <i>British Journal of Haematology</i> , 2019, 187, 174-184.	2.5	23
14	A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. <i>Pathology</i> , 2020, 52, 167-178.	0.6	23
15	DeepSNVMiner: a sequence analysis tool to detect emergent, rare mutations in subsets of cell populations. <i>PeerJ</i> , 2016, 4, e2074.	2.0	23
16	Staging bone marrow in diffuse large B-cell lymphoma: the role of ancillary investigations. <i>Pathology</i> , 2009, 41, 214-222.	0.6	22
17	Occult bone marrow involvement in patients with diffuse large B-cell lymphoma: results of a pilot study. <i>Pathology</i> , 2007, 39, 580-585.	0.6	19
18	Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. <i>Internal Medicine Journal</i> , 2017, 47, 938-951.	0.8	19

#	ARTICLE	IF	CITATIONS
19	A high LDH to absolute lymphocyte count ratio in patients with DLBCL predicts for a poor intratumoral immune response and inferior survival. <i>Oncotarget</i> , 2018, 9, 23620-23627.	1.8	19
20	DNA amplification from formalin-fixed decalcified paraffin-embedded bone marrow trephine specimens: does the duration of storage matter?. <i>Pathology</i> , 2008, 40, 702-706.	0.6	18
21	Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI). <i>Journal of Hematology and Oncology</i> , 2009, 2, 49.	17.0	18
22	Role of Immunohistochemistry in Staging Diffuse Large B-cell Lymphoma (DLBCL). <i>Journal of Histochemistry and Cytochemistry</i> , 2008, 56, 893-900.	2.5	15
23	Outcomes of stage I/II follicular lymphoma in the PET era: an international study from the Australian Lymphoma Alliance. <i>Blood Advances</i> , 2019, 3, 2804-2811.	5.2	15
24	Clinical role of flow cytometry in redefining bone marrow involvement in diffuse large B-cell lymphoma (DLBCL) – a new perspective. <i>Histopathology</i> , 2008, 52, 340-347.	2.9	14
25	Role of plasma cells in Waldenström macroglobulinaemia. <i>Pathology</i> , 2017, 49, 337-345.	0.6	14
26	Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphoma. <i>Oncotarget</i> , 2018, 9, 34644-34657.	1.8	14
27	Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenström Macroglobulinaemia reveals different patterns of clonal evolution. <i>British Journal of Haematology</i> , 2019, 185, 767-770.	2.5	13
28	Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic. <i>HemaSphere</i> , 2020, 4, e433.	2.7	11
29	Role of cell-free DNA in haematological malignancies. <i>Pathology</i> , 2021, 53, 416-426.	0.6	11
30	Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group. <i>Internal Medicine Journal</i> , 2017, 47, 35-49.	0.8	10
31	Delineation of a novel dendritic-like subset in human spleen. <i>Cellular and Molecular Immunology</i> , 2016, 13, 443-450.	10.5	9
32	Genomic characterisation of diffuse large B-cell lymphoma. <i>Pathology</i> , 2021, 53, 367-376.	0.6	9
33	Non-parametric Heat Map Representation of Flow Cytometry Data: Identifying Cellular Changes Associated With Genetic Immunodeficiency Disorders. <i>Frontiers in Immunology</i> , 2019, 10, 2134.	4.8	8
34	Novel therapeutic option for orbital atypical lymphoid hyperplasia. <i>Clinical and Experimental Ophthalmology</i> , 2010, 38, 892-894.	2.6	7
35	Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. <i>Blood Advances</i> , 2021, 5, 2644-2649.	5.2	7
36	Bendamustine Plus Rituximab for the Treatment of Waldenström Macroglobulinaemia: Patient Outcomes and Impact of Bendamustine Dosing. <i>Blood</i> , 2020, 136, 10-11.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Bench work and clinical relevance: a new strategy in pathology education. <i>Pathology</i> , 2008, 40, 707-710.	0.6	3
38	Utilisation of s<scp>FLC</scp> assays â€“ how well do we comply with guidelines?. <i>International Journal of Laboratory Hematology</i> , 2013, 35, 200-210.	1.3	3
39	Management and Outcomes of Diffuse Large B-cell Lymphoma Post-transplant Lymphoproliferative Disorder in the Era of PET and Rituximab: A Multicenter Study From the Australasian Lymphoma Alliance. <i>HemaSphere</i> , 2021, 5, e648.	2.7	3
40	Bleeding Propensity in WaldenstrÃ¶m Macroglobulinemia: Potential Causes and Evaluation. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1843-1857.	3.4	3
41	Immune Thrombocytopenia after Renal Transplantation for IgA Nephropathy. <i>Acta Haematologica</i> , 2007, 117, 65-67.	1.4	2
42	High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(âˆ™/low)/CD38-expression predicts poor survival in diffuse large B cell lymphoma. <i>BMC Cancer</i> , 2020, 20, 1061.	2.6	2
43	Comprehensive genomic testing is required to assess for markers of poor prognosis in multiple myeloma. <i>Pathology</i> , 2022, 54, 111-113.	0.6	2
44	The 'Real World' Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative. <i>Blood</i> , 2019, 134, 3986-3986.	1.4	2
45	Acquired Î±-thalassemia associated with myelodysplastic syndromes. <i>Blood</i> , 2018, 132, 2209-2209.	1.4	1
46	Genomic profiling of CD20 negative diffuse large B cell lymphoma identifies targetable mutations: A case report. <i>EJHaem</i> , 2020, 1, 593-595.	1.0	1
47	Retrospective singleâ€“centre analysis of diagnostic approach to adultâ€“onset haemophagocytic lymphohistiocytosis. <i>Internal Medicine Journal</i> , 2021, 51, 939-947.	0.8	1
48	Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. <i>Internal Medicine Journal</i> , 2021, 51, 1707-1712.	0.8	1
49	Clinical Implications of Immunophenotyping in Staging Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 5279-5279.	1.4	1
50	The Genetic Landscape in Elderly DLBCL Aged > 75 Years in the Australasian Leukaemia & Lymphoma Group NHL29 Iric Trial Identifies New Targetable Mutations. <i>Blood</i> , 2020, 136, 18-20.	1.4	1
51	Extramedullary hematopoiesis: mesenchymal stromal cells from spleen provide an in vitro niche for myelopoiesis. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2022, 58, 429-439.	1.5	1
52	Malignant haematology 2021: impact of recent advances on the diagnostic laboratory. <i>Pathology</i> , 2021, 53, 297-299.	0.6	0
53	Net antitumoral immunity and the predictive power of conventional prognosticators in diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8542-8542.	1.6	0
54	Genetics of Disease Progression in Diffuse Large B-Cell Lymphoma: Clonal Selection and Acquisition of Newly Acquired Somatic Mutations at Relapse. <i>Blood</i> , 2014, 124, 3038-3038.	1.4	0

#	ARTICLE	IF	CITATIONS
55	The NPLHL Tumor Microenvironment Is Markedly Enriched in the Tigit and PD-1 Signalling Axes Compared to Classical Hodgkin Lymphoma. <i>Blood</i> , 2021, 138, 3513-3513.	1.4	0
56	Correlation of Hemophagocytosis with Clinical Criteria of Hemophagocytic Lymphohistiocytosis and Recommendations for Screening Bone Marrow Samples in Adult Patients. <i>Blood</i> , 2020, 136, 37-38.	1.4	0
57	Management and Outcomes of Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder in the PET/CT Era: A Multicentre Study from the Australasian Lymphoma Alliance. <i>Blood</i> , 2020, 136, 36-38.	1.4	0
58	Somatic Mutations Associated with IgVH4-34 FR1 Region Unmutated QW and Ayy Motifs in DLBCL Patients. <i>Blood</i> , 2020, 136, 20-21.	1.4	0